Elsevier

Clinical Nutrition

Volume 31, Issue 5, October 2012, Pages 583-601
Clinical Nutrition

Review
Sarcopenic obesity: A Critical appraisal of the current evidence

https://doi.org/10.1016/j.clnu.2012.06.010Get rights and content

Summary

Sarcopenic obesity (SO) is assuming a prominent role as a risk factor because of the double metabolic burden derived from low muscle mass (sarcopenia) and excess adiposity (obesity). The increase in obesity prevalence rates in older subjects is of concern given the associated disease risks and more limited therapeutic options available in this age group.

This review has two main objectives. The primary objective is to collate results from studies investigating the effects of SO on physical and cardio-metabolic functions. The secondary objective is to evaluate published studies for consistency in methodology, diagnostic criteria, exposure and outcome selection. Large between-study heterogeneity was observed in the application of diagnostic criteria and choice of body composition components for the assessment of SO, which contributes to the inconsistent associations of SO with cardio-metabolic outcomes.

We propose a metabolic load:capacity model of SO given by the ratio between fat mass and fat free mass, and discuss how this could be operationalised. The concept of regional fat distribution could be incorporated into the model and tested in future studies to advance our understanding of SO as a predictor of risk for cardio-metabolic diseases and physical disability.

Introduction

Healthy ageing is associated with physiological, gender-specific changes in body composition which impose an overall minimal load on the control of metabolic and cardiovascular functions.1, 2 A significant deviation from a healthy trajectory of body composition may increase the incidence rate of adverse health events.3 The assessment of body composition is commonly performed by quantifying fat (FM) and fat free mass (FFM) components. These components are often utilized to assess the risk for adverse health outcomes in conditions characterized by abnormal modifications of body composition (e.g., obesity, anorexia, cancer).4 However, in recent years the study of the loss of muscle mass (sarcopenia) has experienced a revitalized research interest,5 promoted by the specific application of in vivo body composition methods (dual energy X-ray absorptiometry (DXA), imaging and spectroscopic methods) for the assessment of the quantitative and qualitative characteristics of skeletal muscle mass.6, 7, 8

The predictive value of sarcopenia for health outcomes relates to the metabolic and functional relationship between muscle mass (MM) and physical strength, mobility and vitality.9, 10, 11 Sarcopenia is associated with an increased risk for age-related decline in muscular strength and functional ability,12, 13 as such as it has been labelled a “silent crippler” because of its association with physical disability, falls, fractures and frailty.9, 10, 11, 14, 15 Loss of MM in older individuals is significantly associated with extended hospital stays, infectious and non-infectious complications and overall mortality.9, 14, 16, 17, 18

However, sarcopenia often co-occurs with an increase in FM, a scenario termed sarcopenic obesity (SO), which may carry the cumulative risk derived from each of the two individual body composition phenotypes.19, 20 On its own, excess adiposity may generate significant adverse health effects (e.g., hypertension, dyslipidaemia, insulin resistance). However, evidence increasingly suggests that these risks may be elevated with the addition of low MM.

The prevalence of SO in older-aged individuals is increasing21, 22, 23 and its impact on physical, metabolic and cardiovascular functions is becoming a primary concern amongst nutritionists, geriatricians and public health officers. The ethio-pathogenesis of SO is complex and multi-factorial factors can interplay, including lifestyle (diet, physical activity, smoking), endocrine (corticosteroids, growth factors, insulin, catecholamines), vascular (endothelial function, coagulation), and immunological (inflammation, reactive oxygen species) factors.24, 25 A unanimous view on the direction of the causality of the associations between these factors is not established.

A simple example of the multi-factorial origin of SO is illustrated in Fig. 1. The diagram describes two hypothetical metabolic scenarios conducive to the onset of the same sarcopenic obese phenotype, which is, however, derived from two different metabolic trajectories, i.e., weight gain and weight loss. Weight gain normally occurs alongside a variable rate of accretion of FFM which can potentially give origin to either an obese (normal FFM accretion) or to a SO (low FFM accretion) phenotype. The direction of the model can be reversed when, for example, morbidly obese subjects (body mass index (BMI) > 40 kg/m2) lose a significant amount of weight but not sufficient to move subjects into the overweight category (BMI < 30 kg/m2), a scenario habitually observed with non-surgical weight loss treatments. Weight loss in these subjects could induce a variable rate of FFM loss and therefore determine the onset of a SO phenotype in obese subjects with more prominent losses in lean tissue mass. The between-subject variability in the composition of the tissue in both positive and negative energy balance has been demonstrated in overfeeding and underfeeding experimental, controlled studies able to control for potential confounding factors such as physical activity or dietary intake. For example, Siervo et al.,26 showed that lean healthy subjects gained 6.0 ± 1.3 kg in body weight after a 9-week stepwise overfeeding and the contribution of FM, measured using a 4-compartment model, to total weight change varied between 11% and 98%. Similarly, two groups of obese men who lost 10% (−10.9 ± 2.6 kg) of their baseline weight following either a VLCD or LCD and the contribution of FM to total weight loss varied between 73% and 106%.27 Additional factors can further add to the variability of body composition changes in states of energy imbalance such as physical activity, dietary macronutrient composition, rate of weight loss, genetics, menopausal state, immobilization, endocrine dysfunctions, inflammatory disorders or pharmacological treatments.28, 29, 30, 31, 32 Recent advances in the allometric modelling of these changes could provide a roadmap for the evaluation of the effects of interventions on body composition.33 These models, along with models of the change in visceral fat with weight/fat change could define the trajectory of the expected changes in fat and lean with weight gain and loss and the ability of specific interventions to modify body composition when weight changes. Unfortunately, these models have not been validated in SO and this should be a priority for future clinical studies.

Section snippets

Diagnosis of sarcopenic obesity

The lack of a unanimous view on the criteria to apply to define low MM and high FM in order to identify cases of SO represents a major clinical and research drawback. The criteria are somewhat arbitrary and study-specific, which may have minimized the predictive value of SO as a health risk factor.12 One of the most commonly used indexes for the definition of sarcopenia is the total appendicular skeletal muscle (ASM) index assessed by DXA.34 Individuals with either an ASM index (kg/m2) lower

Sarcopenic obesity and health risks

In a large longitudinal study of community-dwelling older individuals cardiovascular disease event rates were 23% higher in those with SO compared to either sarcopenic or obese individuals.36 In post-menopausal women SO was associated with lower physical function (gait speed) and cardio-pulmonary fitness (peak VO2 and ventilatory threshold).53 Data from the New Mexico Elder Health Survey showed that SO preceded disability.23 Sarcopenic obesity has also been related to a decline in functional

Sarcopenic obesity: a critical appraisal

The analysis of the literature has highlighted a wide heterogeneity of the criteria applied for the classification of SO, resulting in inconsistent associations between SO and disease risk. A systematic appraisal of this heterogeneity has been conducted and categorized into: 1) methodology (body composition methods utilised); 2) classification (the body composition component and the cut-off points used for the classification of sarcopenia and obesity); 3) adjustment (the methods adopted to

Future directions

Based on epidemiological data there is concern surrounding weight loss in elderly patients. However, to date there have been no studies exploring the effects of moderate weight loss on muscle mass in patients with SO. If excess adipose tissue is providing a lipotoxic pro-inflammatory milieu which is part of the etio-pathology of SO, then weight loss with its attendant reduction in FFA and inflammation should be helpful. This is a major gap in the literature.

Although the mechanism(s) of the

Conclusions

The expected increase in lifespan and childhood obesity represent primary predictors of a forecasted increase of obesity in older subjects, which emphasize the urgency to understand the ethio-pathogenesis of SO for the early prevention of potentially associated health risks. A strategic research agenda which includes mechanistic, epidemiologic and clinical approaches must be prioritized to operationalise the diagnostic criteria and define the causality and the strength of risk associations.

Statement of authorship

The manuscript was conceived by CMP and MS. They discussed the manuscript with all the other authors (JCK, SSR, BCMS) and co-wrote the manuscript. All authors contributed to subsequent analyses and interpretation. All authors contributed to the final revision of the manuscript. The corresponding author (MS) is the guarantor for the manuscript and had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis reported

Conflict of interest

All authors have no conflicts of interest to declare.

References (92)

  • W.C. Stephen et al.

    Sarcopenic-obesity and cardiovascular disease risk in the elderly

    J Nutr Health Aging

    (May 2009)
  • T.N. Kim et al.

    Skeletal muscle mass to visceral fat area ratio is associated with metabolic syndrome and arterial stiffness: the Korean Sarcopenic Obesity Study (KSOS)

    Diabetes Res Clin Pract

    (Aug 2011)
  • H. Honda et al.

    Obese sarcopenia in patients with end-stage renal disease is associated with inflammation and increased mortality

    Am J Clin Nutr

    (Sep 2007)
  • U.G. Kyle et al.

    Increased length of hospital stay in underweight and overweight patients at hospital admission: a controlled population study

    Clin Nutr

    (Feb 2005)
  • M.A. Monteiro et al.

    Temporal parameters of the foot roll-over during walking: influence of obesity and sarcopenic obesity on postmenopausal women

    Maturitas

    (Oct 2010)
  • C.M. Prado et al.

    Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study

    Lancet Oncol

    (Jul 2008)
  • M. Siervo et al.

    Ageing, adiposity indexes and low muscle mass in a clinical sample of overweight and obese women

    Obesity Res Clinical Pract

    (2012)
  • T. Schutz et al.

    Weight gain in long-term survivors of kidney or liver transplantation – another paradigm of sarcopenic obesity?

    Nutrition

    (Apr 2012)
  • M. Cesari et al.

    Sarcopenia, obesity, and inflammation – results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel cardiovascular risk factors study

    Am J Clin Nutr

    (Aug 2005)
  • R. Marcus et al.

    Skeletal muscle fat infiltration: impact of age, inactivity, and exercise

    J Nutr Health Aging

    (2010)
  • J. Bigaard et al.

    Does waist circumference alone explain obesity-related health risk?

    Am J Clin Nutr

    (Sep 2004)
  • L.M. Sparks et al.

    Relation of adipose tissue to metabolic flexibility

    Diabetes Res Clin Pract

    (Jan 2009)
  • D. Gallagher et al.

    Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index

    Am J Clin Nutr

    (Sep 2000)
  • Jackson AS, Janssen I, Sui X, Church TS, Blair SN. Longitudinal changes in body composition associated with healthy...
  • R. Baumgartner

    Age

  • M.-P. St-Onge
    (2005)
  • M. Siervo et al.

    Body composition assessment: theory into practice: Introduction of multicompartment models

    IEEE Eng Med Biol Mag

    (Jan–Feb 2010)
  • E.M. Evans et al.

    A technique to assess body composition and sarcopenia using DXA: application for an obese population

    Eur J Clin Nutr

    (Feb 2010)
  • Y. Nakagawa et al.

    Age-related changes in intramyocellular lipid in humans by in vivo H-MR spectroscopy

    Gerontology

    (2007)
  • L. McCargar

    New insights into body composition and health through imaging analysis. 2007 Ryley-Jeffs memorial lecture

    Can J Diet Pract Res

    (2007 Autumn)
  • R.N. Baumgartner et al.

    Epidemiology of sarcopenia among the elderly in New Mexico

    Am J Epidemiol

    (Apr 15 1998)
  • C.W. Bales et al.

    Sarcopenia, weight loss, and nutritional frailty in the elderly

    Annu Rev Nutr

    (2002)
  • W. Evans

    Functional and metabolic consequences of sarcopenia

    J Nutr

    (May 1997)
  • I. Janssen et al.

    Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability

    J Am Geriatr Soc

    (May 2002)
  • I. Janssen et al.

    Skeletal muscle cutpoints associated with elevated physical disability risk in older men and women

    Am J Epidemiol

    (Feb 15 2004)
  • E.J. Metter et al.

    Skeletal muscle strength as a predictor of all-cause mortality in healthy men

    J Gerontol A Biol Sci Med Sci

    (Oct 2002)
  • G. Cosqueric et al.

    Sarcopenia is predictive of nosocomial infection in care of the elderly

    Br J Nutr

    (Nov 2006)
  • R. Roubenoff

    Sarcopenic obesity: does muscle loss cause fat gain? Lessons from rheumatoid arthritis and osteoarthritis

    Ann N Y Acad Sci

    (May 2000)
  • R. Roubenoff

    Sarcopenic obesity: the confluence of two epidemics

    Obes Res

    (Jun 2004)
  • D.R. Bouchard et al.

    Sarcopenic/obesity and physical capacity in older men and women: data from the Nutrition as a Determinant of Successful Aging (NuAge)-the Quebec longitudinal study

    Obesity (Silver Spring)

    (Apr 16 2009)
  • R.N. Baumgartner et al.

    Sarcopenic obesity predicts instrumental activities of daily living disability in the elderly

    Obes Res

    (Dec 2004)
  • M. Siervo et al.

    Efficiency of autoregulatory homeostatic responses to imposed caloric excess in lean men

    Am J Physiol Endocrinol Metab

    (Feb 2008)
  • M. Siervo et al.

    Use of the cellular model of body composition to describe changes in body water compartments after total fasting, very low calorie diet and low calorie diet in obese men

    Int J Obes (London)

    (May 2010)
  • T.B. Chaston et al.

    Changes in fat-free mass during significant weight loss: a systematic review

    Int J Obes

    (2006)
  • A.G. Dulloo et al.

    Autoregulation of body composition during weight recovery in human: the Minnesota Experiment revisited

    Int J Obes Relat Metab Disord

    (May 1996)
  • Weinheimer EM, Sands LP, Campbell WW. A systematic review of the separate and combined effects of energy restriction...
  • Cited by (419)

    View all citing articles on Scopus
    View full text